ClinicalTrials.gg
CompletedNCT00319553Updated Oct 5, 2012Results posted

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

A Phase 4 interventional study of ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed and BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed in Pertussis, Tetanus and Diphtheria, sponsored by Sanofi. Completed at 10 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-05.

Sponsored by Sanofi · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
647
Allocation
Randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing adacel in Whooping Cough — none open to participants now, none under way, none of them phase 3. adacel · Whooping Cough.

Enrollment
10th of 24
647 · median 523
Started
2006
with 5 others
Phase 4
14 of 24
none open now
Registered
3rd of 24
by date
Lead sponsor
3 of 24
Sanofi

Among the 24 studies testing adacel in Whooping Cough, this one is the 10th largest by enrollment, is one of 6 that started in 2006, is one of 14 in phase 4, and was the 3rd registered.

Whooping Cough

290 studies on the registry are indexed under Whooping Cough; 23 are open to participants now.

Browse Whooping Cough studies →

Open to participants now

None of the 24 studies testing adacel in Whooping Cough is open now. The open studies under Whooping Cough, anywhere →

About adacel

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 14 Whooping Cough studies recruiting now, 2 (14%) set no upper age limit and 11 (79%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing adacel in Whooping Cough as a file.
02

Study summary

This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and BOOSTRIX® vaccines among US adolescents.

03

Conditions studied

  • Pertussis
  • Tetanus
  • Diphtheria

Keywords

  • Tetanus
  • diphtheria
  • acellular pertussis
04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 11 - 18 years of age at the time of vaccination in this trial
  • Signed Institutional Review Board (IRB)-approved informed assent / consent form.
  • Able to attend all scheduled visits and to comply with all trial procedures.
  • For a female, negative serum/urine pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Any condition which, in the opinion of the investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
  • Serious chronic disease (i.e. cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric etc) that is unstable or that might:

    • interfere with the ability to participate fully in the study; or
    • interfere with evaluation of the vaccine.
  • Known or suspected impairment of immunologic function.
  • Febrile illness within the last 72 hours or an oral temperature ≥ 100.4°F (≥ 38°C) at the time of inclusion.
  • History of documented tetanus, diphtheria or pertussis disease within the preceding 5 years.
  • Known or suspected receipt of a tetanus or diphtheria-containing vaccine within the preceding 2 years.
  • Known or suspected receipt of a pertussis-containing vaccine within the preceding 5 years.
  • Administration of immune globulin or other blood products within the last three months, or injected or oral or other therapy expected to materially alter immune function within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting less than 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
  • Received any vaccine in the 21-day period prior to enrollment or scheduled to receive any vaccination after enrollment and prior to visit 2.
  • Suspected or known to any of the vaccine components or to latex.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
647 participants (actual)

Study arms

  • Experimental
    Adacel® Vaccine Group

    Biological: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed

  • Active comparator
    BOOSTRIX® Vaccine Group

    Biological: BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed

Interventions

  • BiologicalADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed

    Drug page: Adacel

    0.5 mL, IM

    Also known as: ADACEL®

  • BiologicalBOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed

    Drug page: Boostrix

    0.5 mL, IM

    Also known as: BOOSTRIX®

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®

    Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia. Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.

    Time frame: Day 0 to 7 post-vaccination

  2. Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.

    Time frame: Day 0 and 28 days post-vaccination

  3. Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.

    Time frame: Day 0 and 28 days post-vaccination

  4. Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.

    Time frame: Day 0 and 28 days post-vaccination

07

Results

Posted Oct 21, 2010

Participant flow

Participants were enrolled from 09 May 2006 to 02 October 2006 in 12 clinical centers in the US.

Participant flow — Overall Study
MilestoneAdacel® Vaccine GroupBoostrix® Vaccine Group
Started323321
Completed319317
Not completed44
Withdrew: Protocol violation12
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject11

Outcome measures

PrimaryNumber of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®

Solicited injection site reactions: Pain, Erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia. Grade 3 reaction definitions: Pain = Incapacitating, unable to perform usual activities; Erythema and swelling = ≥ 5 cm; Fever = temperature ≥ 39.1°C or ≥ 102.3°F; Headache, Malaise, and Myalgia = Prevents daily activities.

Time frame:
Day 0 to 7 post-vaccination
Reported as:
Number · Participants
Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix®
ParticipantsAdacel® Vaccine GroupBoostrix® Vaccine Group
Any solicited injection site reaction273257
Grade 3 solicited injection site reaction54
Any solicited injection site Pain270247
Grade 3 solicited inj. site Pain (Incapacitating)23
Any solicited injection site Erythema7567
Grade 3 solicited injection site Erythema (≥ 5 cm)21
Any solicited injection site Swelling6144
Grade 3 solicited injection site Swelling (≥ 5 cm)21
Any solicited systemic reaction216205
Grade 3 solicited systemic reaction99
Any solicited Fever189
Grade 3 solicited Fever (≥ 39.1°C or ≥ 102.3°F)10
Any solicited Headache136108
Gr 3 solicited Headache: Prevents daily activities34
Any solicited Malaise9178
Gr 3 solicited Malaise: Prevents daily activities86
Any solicited Myalgia167166
Gr 3 solicited Myalgia: Prevents daily activities13
PrimaryPercentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
Time frame:
Day 0 and 28 days post-vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Tetanus Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
Percentage of ParticipantsAdacel® Vaccine GroupBoostrix® Vaccine Group
Tetanus IgG antitoxin ≥0.1 IU/mL :pre-vaccination9998
Tetanus IgG antitoxin ≥0.1 IU/mL :28 days post-vac100100
PrimaryPercentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
Time frame:
Day 0 and 28 days post-vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Diphtheria Antitoxin Concentrations ≥ 0.1 IU/mL Pre- and Post-Vaccination With Adacel® or Boostrix®.
Percentage of ParticipantsAdacel® Vaccine GroupBoostrix® Vaccine Group
Diphtheria IgG antitoxin ≥0.1 IU/mL : pre-vacc9293
Diphtheria IgG antitoxin ≥0.1 IU/mL: 28 D post-vac100100
PrimaryGeometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.
Time frame:
Day 0 and 28 days post-vaccination
Reported as:
Geometric mean · EU/mL
Geometric Mean Concentration of Antibody to Pertussis Antigens Pre- and Post-Vaccination With Adacel® or Boostrix®.
EU/mLAdacel® Vaccine GroupBoostrix® Vaccine Group
Anti-pertussis toxoid IgG: pre-vaccination14.4 (12.5 to 16.6)13.5 (11.6 to 15.8)
Anti-filamentous hemagglutinin IgG:pre-vaccination26.1 (22.7 to 30.0)28.2 (24.5 to 32.4)
Anti-pertactin IgG: pre-vaccination12.4 (10.6 to 14.6)13.1 (11.2 to 15.5)
Anti-fimbriae types 2 and 3 IgG: pre-vaccination13.9 (12.0 to 16.2)14.5 (12.2 to 17.2)
Anti-pertussis toxoid IgG: post-vaccination86.7 (78.8 to 95.4)135.9 (122.9 to 150.2)
Anti-filamentous hemagglutinin IgG post-vaccinat.240.7 (217.7 to 266.1)402.9 (365.5 to 444.2)
Anti-pertactin IgG: post-vaccination322.7 (279.7 to 372.4)463.3 (395.4 to 542.9)
Anti-fimbriae types 2 and 3 IgG: post-vaccination1203 (1004 to 1442)26.6 (22.2 to 31.8)

Adverse events

Collected over Adverse events data were collected from the day of vaccination up to 1 month post-vaccination.. Non-serious events are listed at a 5.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adacel® Vaccine Group—0/323 (0%)273/320 (85.3%)
Boostrix® Vaccine Group—0/321 (0%)257/317 (81.1%)
Most frequent other events
Most frequent other events
EventAdacel® Vaccine GroupBoostrix® Vaccine Group
Solicited injection site PainGeneral disorders270/320257/317
Solicited MyalgiaMusculoskeletal and connective tissue disorders167/320166/317
Solicited HeadacheNervous system disorders136/320108/317
Solicited MalaiseGeneral disorders91/32078/317
Solicited injection site ErythemaGeneral disorders75/32067/316
Solicited injection site SwellingGeneral disorders61/32044/316
Solicited FeverGeneral disorders18/3209/316

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Adacel® Vaccine GroupBoostrix® Vaccine GroupTotal
<=18 years291291582
Between 18 and 65 years323062
>=65 years000
Age Continuous
Age Continuous(years)Adacel® Vaccine GroupBoostrix® Vaccine GroupTotal
Mean14.5 ± 2.3314.7 ± 2.3314.6 ± 2.33
Sex: Female, Male
Sex: Female, Male(Participants)Adacel® Vaccine GroupBoostrix® Vaccine GroupTotal
Female154150304
Male169171340
Region of Enrollment
Region of Enrollment(participants)Adacel® Vaccine GroupBoostrix® Vaccine GroupTotal
United States323321644
08

Study locations

10 sites
  • Annapolis, Maryland 21401, United States
  • Baltimore, Maryland 21201, United States
  • Frederick, Maryland 21702, United States
  • Durham, North Carolina 27704, United States
  • Durham, North Carolina 27705, United States
  • Franklin, Tennessee 37067, United States
  • Bellevue, Washington 98005, United States
  • Mercer Island, Washington 98040-2758, United States
  • Sammamish, Washington 98075, United States
  • Seattle, Washington 98105, United States
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Oct 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2006
First posted
Apr 27, 2006
Start
May 2006
Primary completionActual
Oct 2008
CompletionActual
Dec 2008
Results first posted
Oct 21, 2010
Last update
Oct 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00319553
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
May 2006
Primary completion
Oct 2008
Completion
Dec 2008
Results posted
Oct 21, 2010
Last update
Oct 5, 2012

Study contacts

Medical Director
study director · Sanofi Pasteur Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adacel · Boostrix

Start the discussion